Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 326 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CAP-IT Clear all

Conditions: Heavy Menstrual Bleeding, Fibroid Uterus
Interventions: Groups 1 and 2 myomectomy and uterine artery embolization, respectively, are surgical/procedure, Elagolix Oral Product; Other · Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: AKI
Interventions: Nicotinamide Riboside + Pterostilbene, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Type 1 Diabetes
Interventions: Anti-thymocyte globulin (ATG), verapamil extended release capsule, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 6 Years to 35 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Aurora, Colorado • Gainesville, Florida

Conditions: Knee Osteoarthritis (Knee OA), Chronic Pain, Chronic Knee Pain
Interventions: Duloxetine, Placebo; Drug
Lead sponsor: Benedict Alter; Other
Eligibility: 45 Years to 80 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Inflammation; Muscle
Interventions: ESPO-572®, PCSO-524®; Dietary Supplement
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Psoriasis
Interventions: Internet Survey, fluocinonide 0.05% ointment; Behavioral · Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage
Interventions: Revumenib, Venetoclax, Azacitidine, intrathecal (IT) chemotherapy, Cytarabine, Methotrexate; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 1 Year to 30 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 10
States / cities: San Diego, California • Aurora, Colorado • Atlanta, Georgia + 7 more

Conditions: HIV-1 Infection
Interventions: Darunavir, Ritonavir, Tenofovir disoproxil fumarate, Emtricitabine, Placebo for Tenofovir disoproxil fumarate, Placebo for Maraviroc, Maraviroc; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 37
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 26 more

Conditions: Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission
Interventions: Palbociclib Oral Capsule, Intrathecal Triple Therapy, Dexamethasone, Bortezomib, Dasatinib, Doxorubicin, Ruxolitinib; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Alcoholic Hepatitis
Interventions: Fecal Microbiota Transplantation, Placebo; Biological · Other
Lead sponsor: Prasun Kumar Jalal; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Depression, Palliative Care, Cancer, Mental Disorder
Interventions: Methylphenidate, Placebo, Selective Serotonin Uptake Inhibitor (SSRI); Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Irritable Bowel Syndrome, Constipation
Interventions: Lubiprostone, Placebo, Smartpill wireless motility capsule; Drug · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Obsessive-Compulsive Disorder
Interventions: ExAblate MR-guided Focused Ultrasound Bilateral Anterior Capsulotomy; Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 25 Years to 64 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 2
States / cities: Palo Alto, California • Boston, Massachusetts

Conditions: Opioid Withdrawal
Interventions: Pregabalin 200 MG capsules, Placebo oral tablet, Lofexidine 0.18Mg Tab; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania

Conditions: ACL Reconstruction (ACLR) With a Bone-patellar Tendon-bone (BPTB) Autograft
Interventions: Pacira Iovera Cryoneurolysis device, Placebo/Sham device; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 45 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Pancreatic Adenocarcinoma
Interventions: Tetrahydrouridine, Decitabine; Drug
Lead sponsor: Yogen Saunthararajah; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Aphthous Stomatitis
Interventions: multivitamin; Dietary Supplement
Lead sponsor: UConn Health; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Scheduled Cesarean Sections, Postoperative Pain Management, Side Effects
Interventions: duramorph, placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Smoking, Nicotine Dependence
Interventions: Bupropion; Drug
Lead sponsor: Henry Kranzler; Other
Eligibility: 18 Years and older · Female only
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 3
States / cities: Newark, Delaware • Philadelphia, Pennsylvania

Conditions: Parkinson Disease
Interventions: PF-06412562, Standard of Care Placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: Not listed
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Other Endocrine/Nutritional/Metabolic Disorder
Interventions: Nutritional Supplement Blend; Dietary Supplement
Lead sponsor: Pharmanex; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Austin, Texas • Logan, Utah

Conditions: Solid Tumor, Adult
Interventions: HL-085; Drug
Lead sponsor: Kechow Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: San Marcos, California • Las Vegas, Nevada • Canton, Ohio + 2 more

Conditions: Parkinson's Disease
Interventions: Trans-Resveratrol; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 55 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Shoulder Pain, Chronic Pain, Musculoskeletal Injury
Interventions: Dry Needling, Sham Dry Needling; Device · Other
Lead sponsor: Army-Baylor University Doctoral Program in Physical Therapy; Other
Eligibility: 18 Years to 50 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Myomectomy vs Uterine Artery Embolization vs GnRh Antagonist for AUB-L

Protection From Acute Kidney Injury (AKI) With Basis™ Treatment

Precision Administration of Anti-thymocyte Globulin With or Without Verapamil

Personalized Analgesia Through Central Nervous System Engagement to Unlock Performance

Effectiveness of Two Different Forms of Marine Oil on Indirect Markers of Muscle Damage and Soreness in Untrained Men

Using an Internet Study to Improve Adherence for Psoriasis Patients

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen

Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia

Safety Evaluation of Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis

Methylphenidate for Depressed Cancer Patients Receiving Palliative Care

Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation

Sonication-based OCD Neurosurgical Intervention Via Capsulotomy

Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal

Cryoneurolysis in Anterior Cruciate Ligament Reconstruction (ACLR)

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer

Prevention of Recurrent Aphthous Stomatitis Using Vitamins

Low Pain Prediction in Cesarean Section Patients

Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women

PF 06412562 in Subjects With Advanced Stage Parkinson's Disease

Nutritional Supplement Impact on Metabolic Parameters

Study of HL-085 in Patients With Advanced Solid Tumor Tumors

RESvEraTrol in Parkinson's Disease (RESET)

Feasibility of Near-infrared Spectroscopy to Measure Cortical Pain Pathway (Brain) Activation During Dry Needling